ASH 2021 | The future of CAR-T therapy for multiple myeloma
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, talks on the development of CAR T-cell therapy for multiple myeloma. Over recent years, substantial evidence has been gathered to support the use of CAR-T therapy in heavily pretreated patients. Most recently, these efforts led to the FDA approval of idecabtagene vicleucel (ide-cel) for people with multiple myeloma that have relapsed after or are refractory to at least four prior treatments. Ciltacabtagene autoleucel (cilta-cel), another BCMA-directed therapy with two BCMA-targeting single-domain antibodies designed to confer avidity, is also under FDA review and is expected to be approved in the coming months. Prof. van de Donk comments on continued investigations driving the field forwards, including the assessment of new constructs, and testing in earlier stages of disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
